BioNTech to increase mRNA vaccine footprint in Africa with $145M investment

Katherine Lewin

News Reporter

Moderna may be holding back its plans for mRNA vaccine production in Africa, but Germany’s BioNTech is filling in the space with an expanded partnership …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech to increase mRNA vaccine footprint in Africa with $145M investment

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

FDA hits Camurus with CRL for acromegaly therapy over manufacturing issues

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

Starboard takes activist stake in J&J consumer spinout Kenvue

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

BioN­Tech to in­crease mR­NA vac­cine foot­print in Africa with $145M in­vest­ment

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioNTech to increase mRNA vaccine footprint in Africa with $145M investment